* Skye Bioscience Inc is expected to report resultson November 7 for the period ending September 30 2024
*
* LSEG's mean analyst estimate for Skye Bioscience Inc is for a loss of 25 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Skye Bioscience Inc is $19.00, above its last closing price of $5.35.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.21 -0.19 -0.20 Missed -2.6
Mar. 31 2024 -0.16 -0.16 -0.18 Missed -12.5
Dec. 31 2023 -0.38 -0.38 -0.63 Missed -65.8
This summary was machine generated November 6 at 14:35 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments